MAESTRO
2019
Macitentan in Eisenmenger Syndrome to Restore Exercise Capacity
In 226 patients with Eisenmenger syndrome in WHO functional class II–III, macitentan did not improve 6-minute walk distance compared with placebo.
Result
Primary endpoint: Change from baseline in 6-minute walk distance at week 16
+18.3 m vs +19.7 m; least-squares mean difference −4.7 m (95 % CI −22.8 to 13.5; p=0.612). NT-proBNP fell with macitentan; haemoglobin fell by ≥2 g/dL in 36.0 % vs 8.9 %.
- Subtopic
- Eisenmenger syndrome
- Design
- Phase-3, double-blind, placebo-controlled RCT over 16 weeks
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ESC 2020 ACHDACC/AHA 2025 ACHD
- Source
- Gatzoulis MA, Landzberg M, Beghetti M, et al. Circulation. 2019;139(1):51-63.doi 10.1161/CIRCULATIONAHA.118.033575
Discussion & critique
Clearly negative, but a quarter of patients were already on a PDE5 inhibitor and most were only class II, so the placebo arm walked further than expected and left little room to show benefit, a design problem as much as a drug problem. It stops the BREATHE-5 result from being generalised to the whole endothelin-antagonist class.